Dare Bioscience (DARE) Competitors

$2.37 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.39 +0.02 (+0.84%)

As of 05/22/2026 07:58 PM Eastern

DARE vs. OKUR, ACOG, GNLX, THAR, and CRDF

Should you buy Dare Bioscience stock or one of its competitors? MarketBeat compares Dare Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dare Bioscience include OnKure Therapeutics (OKUR), Alpha Cognition (ACOG), Genelux (GNLX), Tharimmune (THAR), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry.

How does Dare Bioscience compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Dare Bioscience had 9 more articles in the media than OnKure Therapeutics. MarketBeat recorded 10 mentions for Dare Bioscience and 1 mentions for OnKure Therapeutics. Dare Bioscience's average media sentiment score of 0.99 beat OnKure Therapeutics' score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience has higher revenue and earnings than OnKure Therapeutics. Dare Bioscience is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Dare Bioscience	$1.03M	34.47	-$13.40M	-$0.95	N/A

Dare Bioscience's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Dare Bioscience	N/A	N/A	-46.22%

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

OnKure Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

OnKure Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 541.33%. Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 321.94%. Given OnKure Therapeutics' higher probable upside, equities research analysts plainly believe OnKure Therapeutics is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Dare Bioscience beats OnKure Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Alpha Cognition?

Dare Bioscience (NASDAQ:DARE) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Dare Bioscience has higher earnings, but lower revenue than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	34.47	-$13.40M	-$0.95	N/A
Alpha Cognition	$10.22M	12.46	-$20.67M	-$1.35	N/A

In the previous week, Dare Bioscience had 4 more articles in the media than Alpha Cognition. MarketBeat recorded 10 mentions for Dare Bioscience and 6 mentions for Alpha Cognition. Dare Bioscience's average media sentiment score of 0.99 beat Alpha Cognition's score of 0.56 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Dare Bioscience's return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Alpha Cognition	-232.23%	-58.35%	-45.99%

Dare Bioscience presently has a consensus price target of $10.00, suggesting a potential upside of 321.94%. Alpha Cognition has a consensus price target of $16.00, suggesting a potential upside of 173.50%. Given Dare Bioscience's higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

6.7% of Dare Bioscience shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 14.0% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dare Bioscience has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

Summary

Dare Bioscience beats Alpha Cognition on 10 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Genelux?

Genelux (NASDAQ:GNLX) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Genelux currently has a consensus target price of $18.00, suggesting a potential upside of 516.44%. Dare Bioscience has a consensus target price of $10.00, suggesting a potential upside of 321.94%. Given Genelux's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genelux is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Dare Bioscience had 9 more articles in the media than Genelux. MarketBeat recorded 10 mentions for Dare Bioscience and 1 mentions for Genelux. Dare Bioscience's average media sentiment score of 0.99 beat Genelux's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genelux has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Dare Bioscience's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Dare Bioscience	N/A	N/A	-46.22%

Dare Bioscience has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A
Dare Bioscience	$1.03M	34.47	-$13.40M	-$0.95	N/A

37.3% of Genelux shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Dare Bioscience beats Genelux on 8 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Dare Bioscience had 9 more articles in the media than Tharimmune. MarketBeat recorded 10 mentions for Dare Bioscience and 1 mentions for Tharimmune. Dare Bioscience's average media sentiment score of 0.99 beat Tharimmune's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tharimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Dare Bioscience	N/A	N/A	-46.22%

Tharimmune has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Dare Bioscience	$1.03M	34.47	-$13.40M	-$0.95	N/A

Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 321.94%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Dare Bioscience is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Dare Bioscience beats Tharimmune on 10 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Cardiff Oncology?

Dare Bioscience (NASDAQ:DARE) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Dare Bioscience presently has a consensus target price of $10.00, suggesting a potential upside of 321.94%. Cardiff Oncology has a consensus target price of $10.10, suggesting a potential upside of 467.42%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Dare Bioscience has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	34.47	-$13.40M	-$0.95	N/A
Cardiff Oncology	$590K	206.27	-$45.85M	-$0.67	N/A

In the previous week, Dare Bioscience had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 10 mentions for Dare Bioscience and 9 mentions for Cardiff Oncology. Dare Bioscience's average media sentiment score of 0.99 beat Cardiff Oncology's score of -0.13 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dare Bioscience has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Dare Bioscience's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Summary

Dare Bioscience and Cardiff Oncology tied by winning 8 of the 16 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DARE vs. The Competition

Export

Metric	Dare Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.50M	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-2.49	18.74	21.22	25.65
Price / Sales	34.47	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	47.40	7.09	10.37	7.14
Net Income	-$13.40M	$24.45M	$3.57B	$335.98M
7 Day Performance	12.32%	5.45%	6.01%	3.56%
1 Month Performance	12.32%	2.43%	3.52%	2.54%
1 Year Performance	-18.28%	62.98%	34.13%	35.05%

Dare Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DARE Dare Bioscience	2.7527 of 5 stars	$2.37 flat	$10.00 +321.9%	-18.3%	$35.50M	$1.03M	N/A	30	Analyst Upgrade Gap Up
OKUR OnKure Therapeutics	2.6022 of 5 stars	$3.24 +5.2%	$27.00 +733.3%	+95.8%	$130.90M	N/A	N/A	N/A
ACOG Alpha Cognition	4.2541 of 5 stars	$5.91 +2.8%	$16.00 +170.7%	-36.0%	$128.68M	$10.83M	N/A	N/A	Analyst Forecast
GNLX Genelux	1.6694 of 5 stars	$2.83 -0.7%	$18.00 +536.0%	+13.2%	$126.90M	$8K	N/A	10	News Coverage
THAR Tharimmune	0.0069 of 5 stars	$3.26 -9.9%	N/A	+159.3%	$123M	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DARE) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dare Bioscience (DARE) Competitors

DARE vs. OKUR, ACOG, GNLX, THAR, and CRDF

How does Dare Bioscience compare to OnKure Therapeutics?

Summary

How does Dare Bioscience compare to Alpha Cognition?

Summary

How does Dare Bioscience compare to Genelux?

Summary

How does Dare Bioscience compare to Tharimmune?

Summary

How does Dare Bioscience compare to Cardiff Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dare Bioscience (DARE) Competitors

DARE vs. OKUR, ACOG, GNLX, THAR, and CRDF

How does Dare Bioscience compare to OnKure Therapeutics?

Does the media favor OKUR or DARE?

Which has preferable earnings & valuation, OKUR or DARE?

Is OKUR or DARE more profitable?

Do institutionals & insiders have more ownership in OKUR or DARE?

Which has more risk & volatility, OKUR or DARE?

Do analysts prefer OKUR or DARE?

Summary

How does Dare Bioscience compare to Alpha Cognition?

Which has higher valuation & earnings, DARE or ACOG?

Does the media prefer DARE or ACOG?

Is DARE or ACOG more profitable?

Do analysts prefer DARE or ACOG?

Do institutionals and insiders hold more shares of DARE or ACOG?

Which has more risk and volatility, DARE or ACOG?

Summary

How does Dare Bioscience compare to Genelux?

Do analysts recommend GNLX or DARE?

Does the media prefer GNLX or DARE?

Which has more volatility & risk, GNLX or DARE?

Is GNLX or DARE more profitable?

Which has higher valuation and earnings, GNLX or DARE?

Do institutionals & insiders have more ownership in GNLX or DARE?

Summary

How does Dare Bioscience compare to Tharimmune?

Does the media prefer THAR or DARE?

Is THAR or DARE more profitable?

Which has preferable valuation & earnings, THAR or DARE?

Do analysts recommend THAR or DARE?

Which has more volatility and risk, THAR or DARE?

Do institutionals and insiders hold more shares of THAR or DARE?

Summary

How does Dare Bioscience compare to Cardiff Oncology?

Do analysts rate DARE or CRDF?

Which has better earnings & valuation, DARE or CRDF?

Does the media favor DARE or CRDF?

Which has more risk and volatility, DARE or CRDF?

Do insiders and institutionals hold more shares of DARE or CRDF?

Is DARE or CRDF more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools